 |
 |
 |
 |
||
 |
 |
 |
 |
 |
 |
|
Welcome to the SEROQUEL.com Web site.
Schizophrenia and bipolar disorder are two different mental disorders that affect millions of people in the United States. The navigation buttons above will enable you to find information about these illnesses, as well as information about the medication SEROQUEL. SEROQUEL is a psychotropic medication shown to be effective in the treatment of many symptoms of schizophrenia, as well as mania associated with bipolar disorder. Thank you for your interest. SEROQUEL is indicated for the treatment of schizophrenia and the short-term treatment of acute manic episodes associated with bipolar I disorder (in adults over the age of eighteen). Patients should be periodically reassessed to determine the need for continued treatment. Please note that the information provided on this Web site is for educational and informational purposes only. It should not be used as a substitute for seeking professional care for the proper diagnosis and treatment of any psychiatric/medical disorder.
|
Important Information
Prescribing should be consistent with the need to minimize the risk of tardive dyskinesia, seizures, and orthostatic hypotension. A rare condition referred to as neuroleptic malignant syndrome (NMS) has been reported with this class of medications, including SEROQUEL. There have been reports of diabetes mellitus and hyperglycemia related adverse events associated with the use of atypical antipsychotics, including SEROQUEL. Click here to read AstraZeneca’s letter to Health Care Providers. The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials for either schizophrenia or as monotherapy in bipolar mania were somnolence (18%), dizziness (11%), dry mouth (9%), constipation (8%), SGPT increase (5%), dyspepsia (5%), and weight gain (5%). The most commonly observed adverse events associated with the use of SEROQUEL in clinical trials as adjunct therapy with lithium or divalproex in bipolar mania were somnolence (34%), dry mouth (19%), constipation (10%), asthenia (10%), abdominal pain (7%), postural hypotension (7%), pharyngitis (6%), and weight gain (6%). In the elderly and in patients with hepatic impairment, consideration should be given to a lower starting dose, a slower rate of dose titration, careful monitoring during the initial dosing period, and a lower target dose. SEROQUEL® Prescribing Information. AstraZeneca Pharmaceuticals LP, Wilmington, Delaware. |
|
